Sudarshan Pharma Industries Limited has announced the resignation of Umesh Luthra from his position as Independent Director, effective October 18, 2025. The company disclosed this information in a recent filing.

Resignation Details

Luthra, who holds the Director Identification Number (DIN) 06692755, cited pre-occupation as the reason for his departure. In his resignation letter, he stated that there were no other material reasons for his decision to step down from the board.

Transition Process

The outgoing director has requested the company to complete all necessary formalities related to his resignation. This includes filing the required returns with:

• Stock Exchanges
• Ministry of Corporate Affairs
• Registrar of Companies
• Other relevant authorities

Company's Response

Sudarshan Pharma Industries Limited is expected to proceed with the necessary steps to formalize Luthra's resignation and update their records accordingly.

Impact on Board Composition

The resignation of an Independent Director may have implications for the company's board structure and corporate governance. However, the company has not provided any information regarding a potential replacement or changes to the board composition at this time.

About Sudarshan Pharma Industries Limited

Sudarshan Pharma Industries Limited is engaged in the manufacturing of APIs, jobwork manufacturing in pharmaceuticals items, and trading in chemicals and solvents in India. The company specializes in specialty chemicals.

Sudarshan Pharma Industries Limited (SPIL) has announced its unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025, revealing significant developments and strategic moves that underscore the company's growth trajectory.

Financial Performance

SPIL reported robust financial results for the quarter ended September 30, 2025. The company's consolidated revenue stood at ₹17,573.21 crore, with a net profit after tax of ₹544.61 crore for the quarter. These figures demonstrate the company's strong market position and operational efficiency.

Strategic Acquisitions and Expansions

SPIL has made significant strides in expanding its global footprint and manufacturing capabilities:

Dubai Court Award

The company received ₹2.01 crore from a Dubai Court award against Regans International DMCC and Nand Biharilal Chhabaria, with additional amounts pending.

Acquisition in Dubai

On August 5, 2025, SPIL acquired a 100% stake in Cibachem General Trading LLC, Dubai, for ₹55.00 lakhs, marking its entry into the UAE market.

Manufacturing Facility Acquisition

SPIL entered a definitive agreement to acquire an operational manufacturing facility in Telangana from Srigen Lifesciences for ₹25.50 crores, bolstering its production capabilities.

Fund Raising and Financial Strategies

The Board of Directors has approved ambitious fund-raising plans:

• Approval to raise funds up to ₹1,500.00 crores through various securities.
• BSE granted in-principle approval for FCCB issuance up to USD 35 million on September 16, 2025.

Accounting Standards Transition

In a move towards greater financial transparency, SPIL has voluntarily adopted Indian Accounting Standards (Ind AS) with a transition date of April 1, 2024.

Financial Highlights

Outlook

These strategic moves and strong financial performance position Sudarshan Pharma Industries Limited for continued growth in the pharmaceutical and chemical sectors. The company's focus on expanding its manufacturing capabilities and global presence, coupled with its robust financial strategies, indicates a positive outlook for the future.